Marex Group’s Fulcrum Therapeutics FULC Stock Holding History

Marex Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$322K	Buy	+42,000	New	+$390K	﹤0.01%	753

Other funds holding FULC

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marex Group's FULC Position: Q1 2026 in Review

Marex Group opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 42,000 shares worth $322K. The stake represents ﹤0.01% of the portfolio and ranks #753 among its holdings.

169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Marex Group held 42,000 shares of Fulcrum Therapeutics worth $322K as of Q1 2026.
Fulcrum Therapeutics was a new Marex Group position in Q1 2026.
Fulcrum Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #753 holding.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.